Home ► Commmittees ► Medicines Classification ► Recent Gazette Notices

Revised: 8 October 2024

Committees

Recent New Zealand Gazette Notices Relating to Classification

TThe most recent update to the First Schedule to the Medicines Regulations 1984, Medicines Amendment Regulations (No 2) 2021, came into effect on 30 August 2021. Please note that Gazette notices published after 30 August 2021 (listed above) need to be taken into account when seeking the classification of a medicine. .

The current classification of a medicine may also be found in the Classification Database.

8 October 2024 (2024-go5064)

Prescription Medicine

Naproxen, except when otherwise specified in this schedule.

Restricted Medicine

Naproxen; in solid dose forms in medicines containing 250 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of more than 750 milligrams.

Pharmacy-only Medicine

Naproxen; in solid dose forms containing 250 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of not more than 750 milligrams.

8 October 2024 (2024-go5016)

Prescription Medicine

Paracetamol, except when otherwise specified in this schedule.

Restricted Medicine

Paracetamol; in modified-release forms containing 665 milligrams or less, in liquid form in packs containing more than 10 grams and not more than 50 grams.

Pharmacy-only Medicine

Paracetamol; in liquid form in packs containing not more than 10 grams; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

7 October 2024 (2024-go4813)

Prescription Medicines

Alanylglutamine
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Amivantamab
Andexanet alfa
AOH1996
Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose
Articaine; except when used as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Asciminib
Atogepant
Avacopan
Avalglucosidase alfa
Avatrombopag
Belumosudil
Belzutifan
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Bilastine; except when specified elsewhere in this schedule
Body Protective Compound –157
Bufexamac
Cannabidiol; except when elsewhere in the schedule
Cardarine
Cariprazine
Casirivimab
Cemiplimab
Cilgavimab
Ciltacabtagene autoleucel
Clascoterone
Deucravacitinib
Deutetrabenazine
Difelikefalin
Diroximel fumarate
Dostarlimab
Edaravone
Elexacaftor
Enfortumab vedotin
Eslicarbazepine
Estetrol monohydrate
Etesevimab
Faricimab
Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Fenbendazole
Fexofenadine; except for oral use
Filgotinib
Finerenone
Fostemsavir
Fruquintinib
Ganaxolone
Glecaprevir; except when supplied in combination with pibrentasvir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council
Glofitamab
Hyaluronidase
Icosapent ethyl
Imdevimab
Inclisiran
Infigratinib
Ivosidenib
Lemborexant
Lenacapavir
Levomefolic acid; for injection.
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule
Lurbinectedin
Luspatercept
Mavacamten
Mobocertinib
Molnupiravir; except when specified elsewhere in this schedule
Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those authorised by regulation 3, 4 or 5 of the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use
Nirmatrelvir; except when specified elsewhere in this schedule
Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections
Onasemnogene abeparvovec
Opicapone
Osilodrostat
Patisiran
Pegcetacoplan
Pegvaliase
Pemigatinib
Phenol; for injection; except when specified elsewhere in this schedule; except when supplied in a manufacturer’s original pack that has received consent from the Minister or Director-General to a podiatrist registered with the Podiatrists Board of New Zealand for matrixectomy
Pibrentasvir; except when supplied in combination with glecaprevir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the r equirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council
Ponesimod
Pralsetinib
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist, or oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when specified elsewhere in this schedule except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)
Regdanvimab
Relugolix
Ripretinib
Risdiplam
Ritonavir; except when specified elsewhere in this schedule
Sacituzumab govitecan
Selinexor
Selumetinib
Somapacitan
Sotorasib
Sotrovimab
Teneligliptin
Tepotinib
Tezepelumab
Tirzepatide
Tislelizumab
Tixagevimab
Trabectedin
Trastuzumab deruxtecan
Trifarotene
Vericiguat
Vosoritide
Zanubrutinib
Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use except when specified elsewhere in this schedule; except in parenteral nutrition replacement preparations

Restricted Medicines

Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less; except in medicines for injection containing 0.1% for use in practice in an emergency by a dental therapist, an oral health therapist or a dental hygienist registered with the Dental Council
Cannabidiol; when supplied, in medicines with dosing instructions for 150 milligrams or less per day and containing not more than 4.5 grams, when sold in the manufacturer’s original pack that has received consent from the Minister or Director-General, for adults aged 18 years and over, by a registered pharmacist
Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age
Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age
Melatonin; in immediate release preparations containing 5mg or less of melatonin for the treatment of jet lag in adults aged 18 or over, in a manufacturers original pack that has received consent from the Minister or Director-General containing no more than 10 dosage units
Methenamine hippurate
Molnupiravir; for use in the treatment of COVID-19
Nirmatrelvir; for use in the treatment of COVID-19
Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine
Ritonavir; for use in the treatment of COVID-19

Pharmacy-only Medicines

Bilastine; for oral use
Fexofenadine; for oral use except for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing 10 dosage units or less and not more than 10 days’ supply
Folic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose
Folinic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose
Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose
Phenol; in medicines other than for injection containing more than 3% other than for matrixectomy.

Medicines for General Sale

Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing 10 dosage units or less and not more than 10 days’ supply.

10 May 2024 (2024-go2171)

Prescription Medicines

Tezepelumab
Clascoterone
AOH1996
Andexanet alfa
Avatrombopag
Difelikefalin
Ivosidenib
Pralsetinib
Fexofenadine; except for oral use
Phenol; for injection; except when specified elsewhere in this schedule; except when supplied in a manufacturer’s original pack that has received consent from the Minister or Director-General to a podiatrist registered with the Podiatrists Board of New Zealand for matrixectomy

Restricted Medicines

Melatonin; in immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults aged 18 or over, in a manufacturers original pack that has received consent from the Minister or Director-General containing no more than 10 dosage units.

Pharmacy-only Medicines

Fexofenadine; for oral use except for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing 10 dosage units or less and not more than 10 days’ supply
Phenol; in medicines other than for injection containing more than 3% other than for matrixectomy

Medicines for General Sale

Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing 10 dosage units or less and not more than 10 days’ supply

3 May 2024 (2024-go1837)

Prescription Medicines

Alanylglutamine
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Amivantamab
Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose
Articaine; except when used as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Asciminib
Atogepant
Avacopan
Avalglucosidase alfa
Belumosudil
Belzutifan
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Bilastine; except when specified elsewhere in this schedule
Body Protective Compound –157
Bufexamac
Cannabidiol; except when elsewhere in the schedule
Cardarine
Cariprazine
Casirivimab
Cemiplimab
Cilgavimab
Ciltacabtagene autoleucel
Deucravacitinib
Deutetrabenazine
Diroximel fumarate
Dostarlimab
Edaravone
Elexacaftor
Enfortumab vedotin
Eslicarbazepine
Estetrol monohydrate
Etesevimab
Faricimab
Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Fenbendazole
Filgotinib
Finerenone
Fostemsavir
Fruquintinib
Ganaxolone
Glecaprevir; except when supplied in combination with pibrentasvir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council
Glofitamab
Hyaluronidase
Icosapent ethyl
Imdevimab
Inclisiran
Infigratinib
Lemborexant
Lenacapavir
Levomefolic acid; for injection.
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule
Lurbinectedin
Luspatercept
Mavacamten
Mobocertinib
Molnupiravir; except when specified elsewhere in this schedule
Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those authorised by regulation 3, 4 or 5 of the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use
Nirmatrelvir; except when specified elsewhere in this schedule
Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections
Onasemnogene abeparvovec
Opicapone
Osilodrostat
Patisiran
Pegcetacoplan
Pegvaliase
Pemigatinib
Pibrentasvir; except when supplied in combination with glecaprevir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council
Ponesimod
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist, or oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when specified elsewhere in this schedule except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)
Regdanvimab
Relugolix
Ripretinib
Risdiplam
Ritonavir; except when specified elsewhere in this schedule
Sacituzumab govitecan
Selinexor
Selumetinib
Somapacitan
Sotorasib
Sotrovimab
Teneligliptin
Tepotinib
Tirzepatide
Tislelizumab
Tixagevimab
Trabectedin
Trastuzumab deruxtecan
Trifarotene
Vericiguat
Vosoritide
Zanubrutinib
Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use except when specified elsewhere in this schedule; except in parenteral nutrition replacement preparations

Restricted Medicine

Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less; except in medicines for injection containing 0.1% for use in practice in an emergency by a dental therapist, an oral health therapist or a dental hygienist registered with the Dental Council
Cannabidiol; when supplied, in medicines with dosing instructions for 150 milligrams or less per day and containing not more than 4.5 grams, when sold in the manufacturer’s original pack that has received consent from the Minister or Director-General, for adults aged 18 years and over, by a registered pharmacist
Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age
Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age
Methenamine hippurate
Molnupiravir; for use in the treatment of COVID-19
Nirmatrelvir; for use in the treatment of COVID-19
Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine
Ritonavir; for use in the treatment of COVID-19

Pharmacy-only Medicines

Bilastine; for oral use
Folic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose
Folinic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose
Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose

4 December 2023 (2023-go5620)

Restricted Medicines

Methenamine hippurate

3 November 2023 (2023-go5107)

Prescription Medicines

Alanylglutamine
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Amivantamab
Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose
Articaine; except when used as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Asciminib
Atogepant
Avacopan
Avalglucosidase alfa
Belumosudil
Belzutifan
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Bilastine; except when specified elsewhere in this schedule
Body Protective Compound –157
Bufexamac
Cannabidiol; except when elsewhere in the schedule
Cardarine
Cariprazine
Casirivimab
Cemiplimab
Cilgavimab
Ciltacabtagene autoleucel
Deucravacitinib
Deutetrabenazine
Diroximel fumarate
Dostarlimab
Edaravone
Elexacaftor
Enfortumab vedotin
Eslicarbazepine
Estetrol monohydrate
Etesevimab
Faricimab
Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Fenbendazole
Filgotinib
Finerenone
Fostemsavir
Fruquintinib
Ganaxolone
Glecaprevir; except when supplied in combination with pibrentasvir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council
Glofitamab
Hyaluronidase
Icosapent ethyl
Imdevimab
Inclisiran
Infigratinib
Lemborexant
Lenacapavir
Levomefolic acid; for injection.
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule
Lurbinectedin
Luspatercept
Mavacamten
Mobocertinib
Molnupiravir; except when specified elsewhere in this schedule
Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those authorised by regulation 3, 4 or 5 of the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use
Nirmatrelvir; except when specified elsewhere in this schedule
Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections
Onasemnogene abeparvovec
Opicapone
Osilodrostat
Patisiran
Pegcetacoplan
Pegvaliase
Pemigatinib
Pibrentasvir; except when supplied in combination with glecaprevir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council
Ponesimod
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist, or oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when specified elsewhere in this schedule except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council
Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)
Regdanvimab
Relugolix
Ripretinib
Risdiplam
Ritonavir; except when specified elsewhere in this schedule
Sacituzumab govitecan
Selinexor
Selumetinib
Somapacitan
Sotorasib
Sotrovimab
Teneligliptin
Tepotinib
Tirzepatide
Tislelizumab
Tixagevimab
Trabectedin
Trastuzumab deruxtecan
Trifarotene
Vericiguat
Vosoritide
Zanubrutinib
Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use except when specified elsewhere in this schedule; except in parenteral nutrition replacement preparations

Restricted Medicine

Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less; except in medicines for injection containing 0.1% for use in practice in an emergency by a dental therapist, an oral health therapist or a dental hygienist registered with the Dental Council
Cannabidiol; when supplied, in medicines with dosing instructions for 150 milligrams or less per day and containing not more than 4.5 grams, when sold in the manufacturer’s original pack that has received consent from the Minister or Director-General, for adults aged 18 years and over, by a registered pharmacist
Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age
Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age
Molnupiravir; for use in the treatment of COVID-19
Nirmatrelvir; for use in the treatment of COVID-19
Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine
Ritonavir; for use in the treatment of COVID-19

Pharmacy-only Medicines

Bilastine; for oral use
Folic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose
Folinic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose
Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose

17 October 2023 (2023-go4878)

Prescription Medicines

Cannabidiol; except when elsewhere in the schedule.

Restricted Medicines

Cannabidiol; when supplied, in medicines with dosing instructions for 150 milligrams or less per day and containing not more than 4.5 grams, when sold in the manufacturer’s original pack that has received consent from the Minister or Director-General, for adults aged 18 years and over, by a registered pharmacist.

6 September 2023 (2023-go4130)

Prescription Medicines

Asciminib
Atogepant
Avacopan
Avalglucosidase alfa
Bilastine; except when specified elsewhere in this Schedule.
Body Protective Compound –157
Deucravacitinib
Edaravone
Fruquintinib
Ganaxolone
Glecaprevir; except when supplied in combination with pibrentasvir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council.
Glofitamab
Lenacapvir
Mobocertinib
Osilodrostat
Patisiran
Pemigatinib
Pibrentasvir; except when supplied in combination with glecaprevir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council.
Relugolix
Teneligliptin
Tirzepatide
Tislelizumab
Vosoritide
Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use except when specified elsewhere in this schedule; except in parenteral nutrition replacement preparations.

Pharmacy-only Medicines

Bilastine; for oral use.

Medicines for General Sale

Zinc; for external use except zinc chloride in medicines containing more than 5%; for internal use in medicines containing 25 milligrams or less per recommended daily dose; for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose and in packs which have received the consent of the Minister or the Director-General to their distribution as general sale medicines and that are sold in the manufacturer's original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except in parenteral nutrition replacement preparations.

16 August 2023 (2023-go3765)

Prescription Medicines

Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those authorised by regulation 3, 4 or 5 of the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.

24 May 2023 (2023-go2081)

Prescription Medicines

Fenbendazole
Glecaprevir; except when supplied in combination with pibrentasvir for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of the approved training programme, when provided by nurses who meet the requirements of the Nursing Council.
Pibrentasvir; except when supplied in combination with glecaprevir for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of the approved training programme, when provided by nurses who meet the requirements of the Nursing Council.
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist, or oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when specified elsewhere in this schedule except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule.
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.
Articaine; except when used as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.
Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.
Dostarlimab
Diroximel fumarate
Infigratinib
Ponesimod
Selinexor
Selumetinib
Sotorasib
Tepotinib
Belzutifan
Enfortumab vedotin
Lurbinectedin
Mavacamten
Somapacitan

Restricted Medicines

Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less; except in medicines for injection containing 0.1% for use in practice in an emergency by a dental therapist, an oral health therapist or a dental hygienist registered with the Dental Council.

4 May 2023 (2023-go1686)

Prescription Medicines

Cardarine
Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose.
Ripretinib
Faricimab
Deutetrabenazine
Eslicarbazepine
Lemborexant
Luspatercept
Trabectedin
Molnupiravir; except when specified elsewhere in this schedule
Nirmatrelvir; except when specified elsewhere in this schedule
Ritonavir; except when specified elsewhere in this schedule
Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course).
Alanylglutamine
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Cariprazine
Casirivimab
Cemiplimab
Cilgavimab
Elexacaftor
Etesevimab
Filgotinib
Hyaluronidase
Imdevimab
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Onasemnogene abeparvovec
Opicapone
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Regdanvimab
Risdiplam
Sotrovimab
Tixagevimab
Trifarotene
Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections.
Naloxone; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those enabled to do so under the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.
Levomefolic acid; for injection.
Amivantamab
Glu-urea-Lys(ahx)-hbed-CC
Icosapent ethyl
Zanubrutinib
Faricimab
Ciltacabtagene autoleucel
Belumosudil
Estetrol monohydrate
Finerenone
Fostemsavir
Inclisiran
Pegcetacoplan
Pegvaliase
Sacituzumab govitecan
Trastuzumab deruxtecan
Vericiguat
Bufexamac

Restricted Medicines

Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age.
Molnupiravir; for use in the treatment of COVID-19
Nirmatrelvir; for use in the treatment of COVID-19
Ritonavir; for use in the treatment of COVID-19
Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine.

Pharmacy-only Medicines

Folic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
Folinic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age.

1 May 2023 (2023-go1592)

Pharmacy-only Medicines

Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age.

1 December 2022 (2022-go5214)

Restricted Medicines

Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine.

4 November 2022 (2022-go4713)

Prescription Medicines

Cardarine
Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose.
Ripretinib
Faricimab
Deutetrabenazine
Eslicarbazepine
Lemborexant
Luspatercept
Trabectedin
Molnupiravir; except when specified elsewhere in this schedule
Nirmatrelvir; except when specified elsewhere in this schedule
Ritonavir; except when specified elsewhere in this schedule
Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course).
Alanylglutamine
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Cariprazine
Casirivimab
Cemiplimab
Cilgavimab
lexacaftor
esevimab
Filgotinib
Hyaluronidase
Imdevimab
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Onasemnogene abeparvovec
Opicapone
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Regdanvimab
Risdiplam
Sotrovimab
Tixagevimab
Trifarotene
Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections.
Naloxone; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those enabled to do so under the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.
Levomefolic acid; for injection.
Amivantamab
Glu-urea-Lys(ahx)-hbed-CC
Icosapent ethyl
Zanubrutinib
Faricimab
Ciltacabtagene autoleucel
Belumosudil
Estetrol monohydrate
Finerenone
Fostemsavir
Inclisiran
Pegcetacoplan
Pegvaliase
Sacituzumab govitecan
Trastuzumab deruxtecan
Vericiguat
Bufexamac

Restricted Medicines

Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age.
Molnupiravir; for use in the treatment of COVID-19
Nirmatrelvir; for use in the treatment of COVID-19
Ritonavir; for use in the treatment of COVID-19

Pharmacy-only Medicines

Folic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
Folinic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

25 October 2022 (2022-go4386)

Prescription Medicines

Nitrofurantoin; except when supplied for oral use containing 100 mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16-65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections.
Naloxone; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those enabled to do so under the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.
Levomefolic acid; for injection.
Amivantamab
Glu-urea-Lys(ahx)-hbed-CC
Icosapent ethyl
Zanubrutinib
Faricimab
Ciltacabtagene autoleucel
Belumosudil
Estetrol monohydrate
Finerenone
Fostemsavir
Inclisiran
Pegcetacoplan
Pegvaliase
Sacituzumab govitecan
Trastuzumab deruxtecan
Vericiguat
Bufexamac

Pharmacy-only Medicines

Folic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
Folinic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

21 September 2022 (2022-go4004)

Prescription Medicines

Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course).

27 July 2022 (2022-go2856)

Prescription Medicines

Molnupiravir, except when specific elsewhere in this schedule
Nirmatrelvir, except when specific elsewhere in this schedule
Ritonavir, except when specific elsewhere in this schedule

Restricted Medicines

Molnupiravir, for use in the treatment of COVID-19
Nirmatrelvir, for use in the treatment of COVID-19
Ritonavir, for use in the treatment of COVID-19

21 July 2022 (2022-go3006)

Prescription Medicines

Cardarine
Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose.
Ripretinib
Faricimab
Deutetrabenazine
Eslicarbazepine
Lemborexant
Luspatercept
Trabectedin

Restricted Medicine

Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age.

6 May 2022 (2022-go1725)

Prescription Medicines

Alanylglutamine
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Cariprazine
Casirivimab
Cemiplimab
Cilgavimab
Elexacaftor
Etesevimab
Filgotinib
Hyaluronidase
Imdevimab
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Molnupiravir
Onasemnogene abeparvovec
Opicapone
Nirmatrelvir
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Regdanvimab
Risdiplam
Sotrovimab
Tixagevimab
Trifarotene

9 December 2021 (2021-go5269)

Prescription Medicines

Alanylglutamine
Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Cariprazine
Elexacaftor
Filgotinib
Hyaluronidase
Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Onasemnogene abeparvovec
Opicapone
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.
Trifarotene

25 November 2021 (2021-go5108)

Prescription Medicines

Casirivimab
Imdevimab
Regdanvimab
Sotrovimab
Molnupiravir
Tixagevimab
Cilgavimab
Etesevimab
PF-07321332

2 November 2021 (2021-go4592)

Prescription Medicines

Risdiplam
Cemiplimab

4 June 2021 (2021-go2170)

Prescription Medicines

Abemaciclib
Acalabrutinib
Alitretinoin
Alkyl nitrites
Alpelisib
Artemisia annua extract
Avelumab
Avibactam
Baloxavir marboxil
Bamlanivimab
Baricitinib
Benralizumab
Blinatumomab
Brigatinib
Brolucizumab
Budesonide; except when specified elsewhere in this notice
Cabotegravir
Cedazuridine
Cenegermin
Cerliponase alfa
Cilnidipine
Codeine
COVID-19 Vaccines; except when administered by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health
Crisaborole
Daratumumab
Darolutamide
Decitabine
Dextromethorphan; except when specified elsewhere in this notice
DMHA including the isomers 2-amino-6-methylheptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexylamine)
Doravirine
Dulaglutide
Durvalumab
Enasidenib
Entrectinib
Esketamine
Fluticasone; except when specified elsewhere in this notice
Fosnetupitant
Fremanezumab
Galcanezumab
Gilteritinib
Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health
Ibutamoren
Indocyanine green
Inotuzumab ozogamicin
Isatuximab
Isavuconazole
Lanadelumab
Larotrectinib
Lifitegrast
Linaclotide
Lorlatinib
Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist
Meldonium
Metamizole
Methylphenylpiracetam
Midostaurin
Neratinib
Niraparib
Obeticholic acid
Olaratumab
Omberacetam
Opium
Ozanimod
Phenylpiracetam
Plitidepsin
Polatuzumab vedotin
Racetams; except when specified elsewhere in this notice
Remdesivir
Risankizumab
Romosozumab
Safinamide
Siponimod
Squill
Stenabolic (SR9009) and other synthetic REV-ERB agonists
Talazoparib
Tafamidis
Tezacaftor
Tilmanocept
Tivozanib
Tucatinib
Unifiram
Upadacitinib
Voglibose
Voretigene neparvovec
Voxilaprevir

Restricted Medicines

Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged six years and over.
Paracetamol; in modified-release forms containing 665 milligrams or less.

Pharmacy-only Medicines

Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.
Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).
Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing 5 dosage units or less and not more than five days’ supply.
Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).
Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

Medicines for General Sale

Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing five dosage units or less and not more than five days’ supply.

26 May 2021 (2021-go2045) – Corrigendum

In the notice with the above heading, published in the New Zealand Gazette, 4 December 2020, Notice No. 2020-go5551 this corrigendum amends the notice by replacing the entry:

DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine)

With:

DMHA including the isomers 2-amino-6-methylheptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexylamine)

28 April 2021 (2021-go1534)

Prescription Medicines

Measles vaccine; except when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Mumps vaccine; except when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Rubella vaccine; except when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

4 March 2021 (2021-go609)

Prescription Medicines

Acalabrutinib
Alitretinoin
Brolucizumab
Cabotegravir
Cedazuridine
Decitabine
Enasidenib
Fosnetupitant
Fremanezumab
Gilteritinib
Indocyanine green
Isatuximab
Larotrectinib
Ozanimod
Siponimod
Tafamidis
Tucatinib
Voretigene neparvovec

Medicines for General Sale

Fexofenadine; For the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply.
Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180mg or less of fexofenadine hydrochloride with maximum daily dose of 180mg when sold in the manufacturer’s original pack containing 5 dosage units or less and not more than 5 days’ supply.

16 February 2021 (2021-go498)

Prescription Medicines

COVID-19 Vaccines; except when administered by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

17 December 2020 (2020-go5682)

Prescription Medicines

Bamlanivimab
Dulaglutide
Remdesivir

4 December 2020 (2020-go5551)

Prescription Medicines

Abemaciclib
Alkyl nitrites
Alpelisib
Artemisia annua extract
Avelumab
Avibactam
Baricitinib
Baloxavir marboxil
Benralizumab
Blinatumomab
Brigatinib
Budesonide; except when specified elsewhere in this notice.
Cenegermin
Cerliponase alfa
Cilnidipine
Codeine
Crisaborole
Daratumumab
Darolutamide
Dextromethorphan; except when specified elsewhere in this notice.
DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine).
Doravirine
Durvalumab
Entrectinib
Esketamine
Galcanezumab
Fluticasone; except when specified elsewhere in this notice.
Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.
Ibutamoren
Inotuzumab ozogamicin
Isavuconazole
Lanadelumab
Lifitegrast
Linaclotide
Lorlatinib
Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.
Meldonium
Metamizole
Methylphenylpiracetam
Midostaurin
Neratinib
Niraparib
Obeticholic acid
Olaratumab
Omberacetam
Opium
Phenylpiracetam
Plitidepsin
Polatuzumab vedotin
Racetams; except when specified elsewhere in this notice.
Risankizumab
Romosozumab
Safinamide
Squill
Stenabolic (SR9009) and other synthetic REV-ERB agonists
Talazoparib
Tezacaftor
Tilmanocept
Tivozanib
Unifiram
UpadacitinibVoglibose
Voxilaprevir

Restricted Medicines

Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.
Paracetamol; in modified-release forms containing 665 milligrams or less.

Pharmacy-only Medicines

Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.
Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).
Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).
Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

5 November 2020 (2020-go5093)

Prescription Medicines

Codeine

28 October 2020 (2020-go4860)

Prescription Medicines

Measles vaccine; except when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Mumps vaccine; except when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Rubella vaccine; except when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

19 October 2020 (2020-go4832)

Prescription Medicines

Alpelisib
Baloxavir marboxil
Cilnidipine
Darolutamide
Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.
Lorlatinib
Niraparib
Talazoparib

18 May 2020 (2020-go1183)

Prescription Medicines

Artemisia annua extract

29 April 2020 (2020-go1806)

Prescription Medicines

Measles vaccine; except when specified elsewhere in this notice.
Mumps vaccine; except when specified elsewhere in this notice.
Rubella vaccine; except when specified elsewhere in this notice.

Pharmacy-only Medicines

Measles vaccine when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Mumps vaccine when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Rubella vaccine when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

20 March 2020 (2020-go1191)

Prescription Medicines

Avelumab
Baricitinib
Benralizumab
Blinatumomab
Brigatinib
Budesonide; except when specified elsewhere in this notice.
Cerliponase alfa
Crisaborole
Daratumumab
Dextromethorphan; except when specified elsewhere in this notice.
Durvalumab
Fluticasone; except when specified elsewhere in this notice.
Ibutamoren
Inotuzumab ozogamicin
Lanadelumab
Lifitegrast
Linaclotide
Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.
Midostaurin
Neratinib
Obeticholic acid
Olaratumab
Opium
Polatuzumab vedotin
Risankizumab
Romosozumab
Safinamide
Squill
Stenabolic (SR9009) and other synthetic REV-ERB agonists
Tezacaftor
Tilmanocept
Tivozanib
Voxilaprevir

Restricted Medicines

Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.
Paracetamol; in modified-release forms containing 665 milligrams or less.

Pharmacy-only Medicines

Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).
Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).
Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

6 March 2020 (2020-go1038)

Prescription Medicines

Abemaciclib
Alkyl nitrites; except when specified elsewhere in the schedule.
Aniracetam
Avibactam
Bilastine; except when specified elsewhere in this notice.
Cenegermin
Coluracetam
Dimiracetam
DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine).
Doravirine
Entrectinib
Esketamine
Fasoracetam
Galcanezumab
Influenza vaccine; except when administered to a person 13 years of age or over by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.
Isavuconazole
Lanadelumab
Meldonium
Metamizole
Methylphenylpiracetam
Nebracetam
Nefiracetam
Omberacetam
Oxiracetam
Phenylpiracetam
Plitidepsin
Pramiracetam
Racetams; except when specified elsewhere in this notice.
Rolziracetam
Seletracetam
Semaglutide
Sunifiram
Unifiram
Upadacitinib
Voglibose

Pharmacy-only Medicines

Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.

19 December 2019 (2019-go5772)

Prescription Medicines

Polatuzumab vedotin

1 November 2019 (2019-go5030)

Prescription Medicines

Measles vaccine; except when specified elsewhere in this notice.
Mumps vaccine; except when specified elsewhere in this notice.
Rubella vaccine; except when specified elsewhere in this notice.

Pharmacy-only Medicines

Measles vaccine when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Mumps vaccine when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.
Rubella vaccine when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

20 September 2019 (2019-go4411)

Prescription Medicines

Avelumab
Baricitinib
Benralizumab
Blinatumomab
Brigatinib
Budesonide; except when specified elsewhere in this notice.
Cerliponase alfa
Crisaborole
Daratumumab
Dextromethorphan; except when specified elsewhere in this notice.
Durvalumab
Fluticasone; except when specified elsewhere in this notice.
Ibutamoren
Inotuzumab ozogamicin
Lanadelumab
Lifitegrast
Linaclotide
Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.
Midostaurin
Neratinib
Obeticholic acid
Olaratumab
Opium
Risankizumab
Romosozumab
Safinamide
Squill
Stenabolic (SR9009) and other synthetic REV-ERB agonists
Tezacaftor
Tilmanocept
Tivozanib
Voxilaprevir

Restricted Medicines

Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.
Paracetamol; in modified-release forms containing 665 milligrams or less.

Pharmacy-only Medicines

Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).
Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).
Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

12 July 2019 (2019-go3281)

Prescription Medicines

Brigatinib
Budesonide; except when specified elsewhere in this notice.
Crisaborole
Fluticasone; except when specified elsewhere in this notice.
Lanadelumab
Romosozumab
Safinamide
Tilmanocept
Tivozanib

Pharmacy-only Medicines

Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril)
Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

24 June 2019 (2019-go2911)

Prescription Medicines

Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

25 February 2019 (2019-go841)

Prescription Medicines

Avelumab
Baricitinib
Benralizumab
Blinatumomab
Cerliponase alfa
Daratumumab
Dextromethorphan; except when specified elsewhere in this notice.
Durvalumab
Ibutamoren
Inotuzumab ozogamicin
Lifitegrast
Linaclotide
Midostaurin
Neratinib
Obeticholic acid
Olaratumab
Opium
Risankizumab
Squill
Stenabolic (SR9009) and other synthetic REV-ERB agonists
Tezacaftor
Voxilaprevir

Restricted Medicines

Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.
Paracetamol; in modified-release forms containing 665 milligrams or less.

Pharmacy-only Medicines

Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.